KERX Financial Facts

Income taxes: 20K
Net loss: -41.7M
See Full Income Statement

Accrued compensation and related liabilities: 4.92M
Total current liabilities: 18.28M
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 2/24/17 *Est. EPS Growth Rate N/A
Average EPS % Beat Rate -59.8% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +8.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/9/16 Q316 -$0.39-$0.20 -$0.19$6.3M$5.37M N/A Details
8/1/16 Q216 -$0.42-$0.28 -$0.14$9.3M$8.6M N/A Details
4/28/16 Q116 -$0.39-$0.26 -$0.13$6.8M$6.63M N/A Details
2/25/16 Q415 -$0.36-$0.25 -$0.11$5.8M$5.68M N/A Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
2/27/15 Q414 -$0.44-$0.37 -$0.07$569K$1.39M N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details